Content area

|
|

Minimal restsygdom ved maligne blodsygdomme II

Forfatter(e)
Professor Peter Hokland, klinisk assistent Hans Beier Ommen, molekylærbiolog Charlotte Guldborg Nyvold, overlæge Jesper Stentoft, bioanalytiker Karin Brændstrup, bioanalytiker Bodil Lind Andersen, bioanalytiker Lone Siig Mikkelsen & molekylærbiolog Mette Østergaard Århus Universitetshospital, Århus Sygehus, Hæmatologisk Afdeling R
Reference: 
Ugeskr Læger 2009;171(4):232-235
Blad nummer: 
Sidetal: 
232-235
Summary Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences Ugeskr Læger 2009;171(4):232-235 The translation of quantitative polymerase chain reaction technology for the quantitative detection of minimal residual disease (MRD) arising from molecular aberrations in leukaemias has progressed from the pre-clinical setting to daily clinical practice. Thus, it is now part of the mainstay in following patients with chronic myeloid leukaemia treated with the tyrosine kinase inhibitor imatinib. Moreover, the methodology is being integrated in an increasing number of clinical trials, where it is expected to result in more rational and individualized clinical decision-making. A special point in favour of the techniques is the powerful and early detection of disease relapses, in some cases up to one year prior to clinical detection.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Andreas Gothardt Lundh | 02/12
1 Kommentar
af Michael Uldall Steinfath | 01/12
1 Kommentar
af Pedram Kazemi-Esfarjani | 01/12
1 Kommentar
af Bjarne Stigsby | 30/11
2 kommentarer
af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar
af Kaj Seidelin | 29/11
6 kommentarer
af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer